Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00893789 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
A Phase 3 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT00893789 is a Phase 3 study that was terminated before completion, run by Cephalon. The registered enrollment target is 117 participants.
The verdict
NCT00893789, a Phase 3 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).
Interventions
- OTHER Placebo
- DRUG Armodafinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2009-04-30 |
| Est. Completion | 2011-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00893789
The ClinicalTrials.gov registry entry for NCT00893789 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00893789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00893789 about?
NCT00893789 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury". The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).
What is the current status of trial NCT00893789?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2009-04-30. Estimated completion is 2011-01-31.
What interventions are being tested in trial NCT00893789?
The interventions under investigation include: Placebo (OTHER), Armodafinil (DRUG).
Who is sponsoring clinical trial NCT00893789?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.